Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000473308 | SCV000552975 | likely benign | Spastic paraplegia | 2024-03-13 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000594324 | SCV000702728 | uncertain significance | not provided | 2016-11-03 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000765121 | SCV000896343 | uncertain significance | Charlevoix-Saguenay spastic ataxia | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV000594324 | SCV001713619 | uncertain significance | not provided | 2019-07-28 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV001848817 | SCV002105093 | uncertain significance | Hereditary spastic paraplegia | 2021-02-12 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV004999477 | SCV005621876 | likely benign | not specified | 2023-11-10 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004999477 | SCV006071512 | uncertain significance | not specified | 2025-03-24 | criteria provided, single submitter | clinical testing | Variant summary: SACS c.8245A>G (p.Ile2749Val) results in a conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00028 in 1613960 control chromosomes in the gnomAD database, including 1 homozygotes (gnomAD v4). This frequency is not significantly higher than estimated for a pathogenic variant in SACS causing Autosomal Recessive Spastic Ataxia Of Charlevoix-Saguenay (0.00028 vs 0.0079), allowing no conclusion about variant significance. c.8245A>G has been reported in the literature in individuals affected with Ataxia (Ngo_2020). These report(s) do not provide unequivocal conclusions about association of the variant with Autosomal Recessive Spastic Ataxia Of Charlevoix-Saguenay. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication have been ascertained in the context of this evaluation (PMID: 31692161). ClinVar contains an entry for this variant (Variation ID: 411694). Based on the evidence outlined above, the variant was classified as uncertain significance. |